Literature DB >> 26137424

Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy.

Eoin P Flanagan1, Brian G Weinshenker1, Karl N Krecke1, Sean J Pittock1.   

Abstract

Entities:  

Year:  2015        PMID： 26137424      PMCID： PMC4404285          DOI： 10.1212/CPJ.0000000000000104

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  7 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  High-risk syndrome for neuromyelitis optica: a descriptive and comparative study.

Authors:  N Collongues; R Marignier; H Zéphir; F Blanc; S Vukusic; O Outteryck; M Fleury; A Ruet; F Borgel; E Thouvenot; T Moreau; G Defer; N Derache; J Pelletier; B Audoin; M Debouverie; P Labauge; O Gout; W Camu; D Brassat; B Brochet; P Vermersch; C Confavreux; J de Seze
Journal:  Mult Scler       Date:  2011-01-14       Impact factor: 6.312

3.  Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.

Authors:  J W Thorpe; D Kidd; I F Moseley; B E Kenndall; A J Thompson; D G MacManus; W I McDonald; D H Miller
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

4.  Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker; Karl N Krecke; Vanda A Lennon; Claudia F Lucchinetti; Andrew McKeon; Dean M Wingerchuk; Elizabeth A Shuster; Yujuan Jiao; Erika S Horta; Sean J Pittock
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

5.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

6.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

7.  Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

Authors:  Su-Hyun Kim; Woojun Kim; Xue Feng Li; In-Ja Jung; Ho Jin Kim
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312
  7 in total
  6 in total

Review 1.  Magnetic resonance imaging in immune-mediated myelopathies.

Authors:  M J Wendebourg; S Nagy; T Derfuss; K Parmar; R Schlaeger
Journal:  J Neurol       Date:  2019-01-29       Impact factor: 4.849

Review 2.  Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.

Authors:  Sean J Pittock; Claudia F Lucchinetti
Journal:  Ann N Y Acad Sci       Date:  2015-06-10       Impact factor: 5.691

Review 3.  A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.

Authors:  Jacqueline M Solomon; Friedemann Paul; Claudia Chien; Jiwon Oh; Dalia L Rotstein
Journal:  Ther Adv Neurol Disord       Date:  2021-05-09       Impact factor: 6.570

Review 4.  Neuromyelitis optica spectrum disorders: An update.

Authors:  Lekha Pandit
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

Review 5.  Advances in spinal cord imaging in multiple sclerosis.

Authors:  Marcello Moccia; Serena Ruggieri; Antonio Ianniello; Ahmed Toosy; Carlo Pozzilli; Olga Ciccarelli
Journal:  Ther Adv Neurol Disord       Date:  2019-04-22       Impact factor: 6.570

6.  Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.

Authors:  Omar Abdel-Mannan; Ainat Klein; Anat Bachar Zipori; Liat Ben-Sira; Aviva Fattal-Valevski; Yael Hacohen; Hadas Meirson
Journal:  Mult Scler       Date:  2022-04       Impact factor: 6.312
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.